-+ 0.00%
-+ 0.00%
-+ 0.00%

Eupraxia presents RESOLVE Phase 1b/2 EP-104GI trial data at DDW meeting

PUBT·04/22/2026 11:05:02
Listen to the news
Eupraxia presents RESOLVE Phase 1b/2 EP-104GI trial data at DDW meeting
  • Eupraxia Pharmaceuticals scheduled new clinical data presentations from ongoing Phase 1b/2 RESOLVE trial of EP-104GI in eosinophilic esophagitis at Digestive Disease Week in Chicago on May 2-5, 2026.
  • Presentations will outline sustained improvements over 36 weeks following escalating doses or single administration, covering tissue-level disease activity, endoscopic signs, swallowing symptoms.
  • Additional DDW disclosures will address dose selection and injection pattern intended to support further development of EP-104GI.
  • Management set a virtual investor event for May 4 to frame commercial opportunity for EP-104GI in prevention of recurrent esophageal strictures, emphasizing potential to reduce repeat interventions via long-acting local steroid delivery.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eupraxia Pharmaceuticals Inc. published the original content used to generate this news brief on April 22, 2026, and is solely responsible for the information contained therein.